Evercore ISI analyst Elizabeth Anderson is adding Cardinal Health to the firm’s “Tactical Outperform” list ahead of Q3 earnings from the Healthcare Technology and Distribution group. Despite the COVID headwind and Optum contract loss, the firm sees Cardinal’s FY25 EPS guidance as “achievable,” driven by solid utilization trends and the offset of new contract wins, says the analyst, who adds that Cardinal has “the cleanest story of all 3 distributors.” Evercore has an In Line rating and $125 price target on Cardinal shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- T2 Biosystems enters exclusive U.S. agreement with Cardinal Health
- Cardinal Health to acquire Integrated Oncology Network for $1.115B in cash
- Telix announces Cardinal Health as U.S. commercial distributor for Zircaix
- Cardinal Health price target raised to $125 from $115 at Argus
- Cardinal Health Board Members to Exit in 2024